oxycodone controlled release / Generic mfg. - LARVOL DELTA

No-PAIN: NSAID Use After Robotic Partial Nephrectomy (clinicaltrials.gov) - P2 | N=110 | Recruiting | Sponsor: University of Miami | Trial completion date: Sep 2026 ➔ Dec 2026

Trial completion date • Genito-urinary Cancer • Kidney Cancer • Oncology • Pain • Renal Cell Carcinoma • Solid Tumor

Complete recovery of thrombotic microangiopathy with severe acute kidney injury due to intravenous use of modified release oxycodone. (PubMed, Clin Kidney J) - "Accordingly, supportive management without the need for invasive and costly interventions may be appropriate in selected cases. Awareness of the association between intravenous OxyContin® use and TMA is essential for timely diagnosis, as identification often depends on direct inquiry regarding drug exposure."

Journal • Acute Kidney Injury • Nephrology • Renal Disease

Non-Narcotic Pain Control After ACL Reconstruction (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: The Cleveland Clinic | Phase classification: P3 ➔ P2

Phase classification • Pain

Short-term risk of falls among initiators of controlled-release tapentadol versus oxycodone in New South Wales between 2014 and 2020: A population-based retrospective cohort study. (PubMed, PLoS Med) - "Tapentadol (SR) was associated with a lower risk of falls than oxycodone (CR) up to four weeks after initiation, although absolute differences were small. The reduction in risk may be an important consideration in older patients where the consequences of falls are most severe."

Clinical • Journal • Retrospective data • Addiction (Opioid and Alcohol)

Analgesic strategies in the management of postoperative pain following uterine artery embolization for symptomatic fibroids: a systematic review. (PubMed, Acta Cir Bras) - "In the ischemic phase of post-uterine artery embolization pain, a superior hypogastric nerve block appears to provide the most consistent relief, with intra-arterial lidocaine representing an alternative when resources are limited. For the inflammatory phase, intravenous dexamethasone is the preferred option, whereas controlled-release oxycodone may be considered only in refractory cases."

Journal • Review • Anesthesia • Pain • Solid Tumor • Uterine Leiomyoma

Purdue's development of abuse-deterrent formulation opioids as a response to market competition: An industry documents analysis. (PubMed, SSM Qual Res Health) - "The overpromotion and overprescription of oxycodone and Purdue Pharma's branded formulation, OxyContin, have been implicated as key drivers of the opioid overdose crisis...Pharmaceutical companies may focus on strategies such as abuse-deterrent formulations to protect market share rather than to protect public health. Regulators should be aware of the potential risks of encouraging this approach."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Pain

Non-Narcotic Pain Control After ACL Reconstruction (clinicaltrials.gov) - P3 | N=30 | Active, not recruiting | Sponsor: The Cleveland Clinic | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2026 ➔ Jun 2027 | Trial primary completion date: Sep 2026 ➔ Jun 2026

Enrollment closed • Trial completion date • Trial primary completion date • Pain

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial (clinicaltrials.gov) - P2 | N=170 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Dec 2026 ➔ May 2027 | Trial primary completion date: May 2026 ➔ May 2027

Trial completion date • Trial primary completion date • Oncology • Ovarian Cancer

OxyContin reformulation and drug-related-arrest rates, property-related crimes, child maltreatment and food pantry participation. (PubMed, Front Pharmacol) - "We find evidence consistent with a positive causal relationship between the OxyContin reformulation, arrest rates for drug abuse violations, and rates for motor vehicle theft. Findings indicate that future drug policies should more carefully consider the various needs of opioid users and potential negative externalities following the implementation of new policies."

Journal • Addiction (Opioid and Alcohol)

Impact of health policies on opioid tapering and discontinuation among patients receiving long-term opioid therapy for chronic noncancer pain. (PubMed, Int J Drug Policy) - "Rapid opioid tapering and discontinuation among individuals receiving LTOT were shaped by opioid-related policies in BC. Caution is needed in implementing opioid-related policy to avoid unintended consequences."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Infectious Disease • Novel Coronavirus Disease • Oncology • Pain • Substance Abuse

3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain (clinicaltrials.gov) - P2 | N=177 | Not yet recruiting | Sponsor: 3D Medicines | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Oncology • Pain

Rebound pain after volar plate surgery in infraclavicular brachial plexus block with ropivacaine 3.75 mg/ml compared with 7.5 mg/ml. A prospective, triple blinded randomised controlled trial (clinicaltrialsregister.eu) - P4 | N=80 | Active, not recruiting | Sponsor: Oslo University Hospital HF | Recruiting ➔ Active, not recruiting

Enrollment closed • Musculoskeletal Diseases • Orthopedics • Pain

Can Naldemedine Allow Higher Oxycodone Dosing in Patients with Cancer? A Single-Center Retrospective Study. (PubMed, J Palliat Med) - "Naldemedine enabled higher oxycodone dosing, suggesting OIC management reduces opioid switching."

Journal • Retrospective data • Constipation • Gastroenterology • Gastrointestinal Disorder • Oncology • Pain

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial (clinicaltrials.gov) - P2 | N=170 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial primary completion date: Feb 2026 ➔ May 2026

Trial primary completion date • Oncology • Ovarian Cancer

Considerations of Vertebrogenic Lower Back Pain After Basil-Vertebral Nerve Ablation (BVNA) Complicated in a Postmenopausal Woman (ASRA-FALL 2025) - "Background & Rationale Chronic Low Back Pain (CLBP) & Osteoporosis CLBP is a leading cause of disability in older adults Vertebral endplate pathologies, including Modic changes, are linked to persistent back pain BVNA is increasingly used for CLBP but remains relatively contraindicated in osteoporosis (T-score < –2.5) Knowledge Gap Few studies document Modic changes post-BVNA in osteoporotic patients High-risk populations (postmenopausal women, prior spinal surgery) require careful pre-procedural screening Considerations of Vertebrogenic Lower Back Pain After Basivertebral Nerve Ablation (BVNA) Complicated in a Postmenopausal Woman: Case Report Case Summary Patient Overview 63-year-old female with history of OSA, hypertension, GERD, IBS, osteoporosis, prior L3–S1 microdiscectomy Persistent postsurgical low back pain treated with L3–L5 medial branch RFA and L5–S1 BVNA Clinical Presentation Pain: stabbing, burning, tingling; worsened with flexion/extension;..."

Clinical • Back Pain • Cardiovascular • Gastroesophageal Reflux Disease • Hypertension • Lumbar Back Pain • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoporosis • Pain • Rheumatology

From addiction to aggression: The spillover effects of opioid policies on intimate partner violence. (PubMed, J Health Econ) - "We investigate how a key supply-side intervention - the abuse-deterrent reformulation of a widely-diverted opioid, OxyContin - affected IPV...The reformulation reduced IPV only in states with smaller illicit drug markets, while states with larger illicit drug markets experienced increased heroin-involved IPV due to substitution towards illicit opioids. Our results underscore the importance of identifying populations at high risk of substitution to illicit opioids and moderating this risk with evidence-based policies."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry • Substance Abuse

No-PAIN: NSAID Use After Robotic Partial Nephrectomy (clinicaltrials.gov) - P2 | N=110 | Recruiting | Sponsor: University of Miami | Trial completion date: Sep 2025 ➔ Sep 2026 | Trial primary completion date: Sep 2025 ➔ Sep 2026

Trial completion date • Trial primary completion date • Genito-urinary Cancer • Kidney Cancer • Oncology • Pain • Renal Cell Carcinoma • Solid Tumor

Accountability in global health systems: insights from a network analysis of Purdue Pharmaceuticals. (PubMed, Global Health) - "Beginning in 1996, Purdue Pharmaceuticals (Purdue) knowingly mislabeled and mass marketed OxyContin (oxycodone), an opioid painkiller, catalyzing the opioid crisis which has been responsible for more than 600 000 deaths in and beyond North America...Through this in-depth examination of the complex interactions involved in global health and pharmaceutical systems, this study offers a nuanced understanding of the diverse actors mobilized and the unique strengths leveraged within and by accountability networks. Further, in examining these networks' differences, interconnectedness, and peculiarities, we broaden the scope of how accountability is defined, conceptualized, and operationalized in global health systems."

Journal • Pain

Non-Narcotic Pain Control After ACL Reconstruction (clinicaltrials.gov) - P3 | N=30 | Recruiting | Sponsor: The Cleveland Clinic | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Sep 2026

Trial completion date • Trial primary completion date • Pain

Postmarketing Research for Opioid Abuse-Deterrent Formulations: A Narrative Review. (PubMed, J Pain Res) - "Currently, 4 opioid formulations carry the ADF designation: XTAMPZA® ER (oxycodone), OXYCONTIN® (oxycodone hydrochloride), HYSINGLA™ ER (hydrocodone bitartrate), and ROXYBOND™ (oxycodone hydrochloride). Of note, XTAMPZA ER has shown sustained lower levels of nonoral abuse or misuse compared with other ADFs, despite a substantial increase in dispensed prescriptions since its launch in 2016. Additional postmarketing research is needed, especially for HYSINGLA ER and ROXYBOND."

Journal • P4 data • Review • Pain

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial (clinicaltrials.gov) - P2 | N=170 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Jul 2026 ➔ Dec 2026 | Trial primary completion date: Jul 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Oncology

From dealer to doctor: A case study examining how Purdue Pharma sought to leverage racial health disparities to attenuate flagging OxyContin sales. (PubMed, Soc Sci Med) - "We contextualize the results to underline the importance of processes of structural racism to segmenting the pain management and substance use treatment markets in a manner that sought to capitalize on the very racism that prevented Asian, Black, Indigenous and Latino patients from obtaining pharmaceutical relief in the earlier days of the epidemic. We conclude that, (1) in absence of stronger federal regulation, especially in light of the recent reversal of the Chevron doctrine, local and state regulatory policies have found considerable success in limiting pharmaceutical excess, and policy at subnational levels will continue to be essential as the opioid epidemic still rages; and (2) greater use of resources such as the opioid industry documents can provide novel insight into processes of structural racism and offer targets for counter-intervention strategies."

Journal • Pain

US reaches a final $7.4bn settlement on opioid oxycontin, cause of 850 000 deaths. (PubMed, BMJ) - No abstract available

Journal

Understanding the demographics of the opioid overdose death crisis. (PubMed, J Popul Econ) - "Additionally, I analyze the long-term impacts of OxyContin's launch, discovering that it induced substantial differences in overdose rates by sex and education...This research highlights how certain groups have been disproportionately affected by the opioid crisis and the foundational role of supply-side shocks to opioid access in explaining the demographics of the overdose death crisis. The online version contains supplementary material available at 10.1007/s00148-025-01108-0."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders

Epidemiology of Fentanyl Overdose: A Comprehensive Review (CPDD 2025) - "Financial Support : Substance Abuse Epidemiology Training Program (SAETP) at Columbia University T32DA031099 Aims: The first wave of the opioid epidemic began in the mid-1990s with the production and marketing of oxycontin. The surge in fentanyl-related deaths is exacerbated by polysubstance use, notably the combination of fentanyl with other substances like xylazine, elevating the risk of fatal outcomes. Significant increases in fentanyl-related overdose deaths have been observed among adolescents, young adults, and Black individuals. Fentanyl overdose deaths surged in Eastern states and were higher in urban areas."

Clinical • Review • Addiction (Opioid and Alcohol) • Substance Abuse